Navigation Links
Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Date:11/18/2013

e no flu-like symptoms, no treatment-related elevations of liver enzymes greater than three times upper limit of normal, no abnormalities in renal function and no clinically meaningful changes in other laboratory values.

"We have now demonstrated that ISIS-APOCIIIRx has the ability to lower triglycerides equally well in patients with high to severely high triglycerides as well as in patients with high triglycerides and type 2 diabetes.  We have demonstrated that ISIS-APOCIIIRx can work equally well as a single agent and in combination with fibrates to produce significant reductions in apoC-III and triglycerides, and increases in HDL-C.  In addition, the observed positive effect of ISIS-APOCIIIRx treatment on lipid parameters, improvements in glucose control and trends toward improvements in insulin sensitivity, suggest that ISIS-APOCIIIRx could have a very attractive therapeutic profile for patients with severely high triglycerides, who often also have diabetes or metabolic syndrome," said Richard Geary, Ph.D., senior vice president of development at Isis. 

ISIS-APOCIIIRx is an antisense drug intended to treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.  ISIS-APOCIIIRx targets apoC-III, a protein produced in the liver that plays a central role in the regulation of serum triglycerides.  Humans who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease.  In clinical studies, patients with lower levels of apoC-III and triglycerides exhibit lower cardiovascular event rates.  Humans with elevated levels of apoC-III have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome.  In addition, the prevalence of type 2 diabetes i
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... SCOTTSDALE, Ariz. and WASHINGTON, June 15, 2011 The ... and CAQH CORE ® (Committee on Operating Rules ... collaborate on activities related to harmonizing electronic data interchange ... NCPDP and CAQH CORE began exploring the ...
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that it has received U.S. Food and Drug ... AFX™ Endovascular AAA System, for the treatment of abdominal ... Annual Meeting of the Society for Vascular Surgery (SVS), ...
Cached Medicine Technology:NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3Endologix Announces FDA Approval of AFX™ Endovascular AAA System 2Endologix Announces FDA Approval of AFX™ Endovascular AAA System 3
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am ... subsequent archived replay of the Company’s presentation may be accessed via the investor relations ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 ... Lava Springs, California’s northernmost and among its least visited State Parks. The volcanic ... whose main outflow is at Ahjumawi Lava Springs, part of the Fall River ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from ... rooms in recent years, according to the American Dental Association. According to a study ... visits went from 1.1 million in a single year to 2.2 million a year. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... decline by 39 percent, according to market research compiled for the National Association ... the U.S. Department of Labor, Bureau of Labor Statistics. As the number of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... DEXTER, Mich., Oct. 16 ReCellular, Inc., ... used wireless phones and,accessories, today announced it ... Cellular ( http://www.consumercellular.com ), one of,the nation,s ... to,collect wireless handsets for recycling from their ...
... 16 HLTH Corporation,(Nasdaq: HLTH ) today announced ... ended September 30, 2007 at approximately 4:00 pm (ET) ... announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. (Nasdaq: ... financial results for the three months ended September 30,2007 ...
... Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ASV) today ... $62 million for the third,quarter of 2007 compared ... quarter,of 2006. As previously announced, Aspreva will ... 2007. The Company will hold a conference,call and ...
... from yogurt(TM) in an easy-to-swallow caplet., VANCOUVER, ... launch of AccuFlora Pro-Biotic Acidophilus, a combination of,five ... and,supports a healthy immune system with the good ... to MayoClinic.com, there is growing public and scientific,interest ...
... of G&D, Dr. Michael Cleary (Stanford University School of ... critical player in the establishment of leukemia stem cells, ... leukemia (MLL) is a distinctive type of leukemia ... by the presence of a break and rearrangement of ...
... CHICAGO, Oct. 16 The Cambridge Group, a ... Carrie Shea,principals of the firm. Mr. Miller ... and,industry experience to The Cambridge Group. In his ... improvements in senior,executive and consulting positions. In his ...
Cached Medicine News:Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 2Health News:ReCellular Named Exclusive Cell Phone Recycling Partner for Consumer Cellular 3Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Northwest Natural Products Introduces AccuFlora(R) 2Health News:The Cambridge Group Names Two New Principals 2
... Designed To Be Used With The Gills ... On The Cornea For Making Limbal Relaxing Incisions., ... The Gills Nomograms. 6mm & 8mm Chord Length ... Relaxing Incisions.5mm Inner Circle Assists In Sizing A ...
... This System Is Designed To Manually Dilate ... Efficacy. The Bimanual Technique Maximizes Safety By ... Parallel, Rather Than Perpendicular, To The Plane ... Risk Of Inadvertent Capsule Tears. Pupil Stretching ...
... To Rest Either Nasally Or Temporally ... Allowing Eyelids To Be Opened From ... Possible Aperture., ,Open And Close With ... To The Globe During Clear Corneal ...
... Unique Reversible Speculums Designed To Rest ... Flipping The Speculums Over, Allowing Eyelids ... Fissures To The Widest Possible Aperture.,Open ... Unobstructed Around-The-Clock Access To The Globe ...
Medicine Products: